ProCE Banner Activity

KEYNOTE-199: Phase II Study of Pembrolizumab in Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage
In this phase II study, pembrolizumab showed antitumor activity in a subset of previously treated patients with metastatic CRPC regardless of PD-L1 expression status.

Released: June 08, 2018

Expiration: June 07, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen